- Home
- PHAR vs LFMD Comparison
PHAR vs LFMD Comparison
Compare PHAR & LFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- LFMD
- Stock Information
- Founded
- PHAR 1988
- LFMD 1994
- Country
- PHAR Netherlands
- LFMD United States
- Employees
- PHAR N/A
- LFMD N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- LFMD Medical/Nursing Services
- Sector
- PHAR Health Care
- LFMD Health Care
- Exchange
- PHAR Nasdaq
- LFMD Nasdaq
- Market Cap
- PHAR 731.1M
- LFMD 619.0M
- IPO Year
- PHAR N/A
- LFMD N/A
- Fundamental
- Price
- PHAR $10.00
- LFMD $11.26
- Analyst Decision
- PHAR Strong Buy
- LFMD Strong Buy
- Analyst Count
- PHAR 3
- LFMD 5
- Target Price
- PHAR $30.00
- LFMD $12.20
- AVG Volume (30 Days)
- PHAR 3.6K
- LFMD 1.9M
- Earning Date
- PHAR 07-31-2025
- LFMD 08-06-2025
- Dividend Yield
- PHAR N/A
- LFMD N/A
- EPS Growth
- PHAR N/A
- LFMD N/A
- EPS
- PHAR N/A
- LFMD N/A
- Revenue
- PHAR $320,708,000.00
- LFMD $234,007,330.00
- Revenue This Year
- PHAR $13.31
- LFMD $29.80
- Revenue Next Year
- PHAR $7.68
- LFMD $18.03
- P/E Ratio
- PHAR N/A
- LFMD N/A
- Revenue Growth
- PHAR 24.13
- LFMD 43.07
- 52 Week Low
- PHAR $6.65
- LFMD $3.99
- 52 Week High
- PHAR $12.61
- LFMD $15.84
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- LFMD 39.59
- Support Level
- PHAR $9.99
- LFMD $11.63
- Resistance Level
- PHAR $10.59
- LFMD $14.43
- Average True Range (ATR)
- PHAR 0.35
- LFMD 0.83
- MACD
- PHAR -0.14
- LFMD -0.39
- Stochastic Oscillator
- PHAR 7.45
- LFMD 0.76
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About LFMD LifeMD Inc.
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.